Bill Sibold is Executive Vice President and Head of Sanofi Genzyme. In this role, he is a member of the Sanofi Executive Committee. Previously, Bill was head of Sanofi Genzyme's Global Multiple Sclerosis, Oncology and Immunology organization, and led the preparation for the global launches of two important new immunology treatments.
Bill joined Sanofi Genzyme in late 2011 as head of the MS franchise where he oversaw the successful launches of its two MS treatments. As head of Sanofi Genzyme, he leads the business’s efforts to maintain its leadership in rare diseases while continuing to grow in multiple sclerosis, oncology and immunology.
Bill has more than 25 years of experience in the biopharmaceutical industry since starting his career with Eli Lilly. He held a number of leadership positions within Biogen, including driving their U.S. commercial operations in neurology, oncology and rheumatology and general management of Biogen's Australian and Asia-Pacific business.
In addition to his time with Biogen, Bill also served as the chief commercial officer of Avanir Pharmaceuticals. He holds an MBA from Harvard Business School and a BA in Molecular Biophysics and Biochemistry from Yale University.